Lori Valigra

The Wellcome Trust is reaching outside the UK to fund translational research and derisk projects for future investors.

Tax credits, specific project funding and deep-pocketed syndicates hit the radar as the biotech industry scrapes around for money.

Investing in innovation during a tight economy could provide a leg up for funders and start-ups once the turnaround comes, a Science|Business conference heard.

Select companies can still find funding from venture capitalists and the public market; others are using the depressed economy to cut costs.

They both come armed with broad plans to stimulate innovation, but the U.S. presidential hopefuls may face their own funding gap amid the flailing economy.

A team of highly creative intrapreneurs is key to the growth of large corporations, delegates heard at the MIT Emerging Technologies Conference.

Financial incentives have attracted the Max Planck Society and an MIT lab to Florida. But can clusters be built on money alone?

For the first time in 30 years, there were no venture-backed IPOs in the US in the second quarter of 2008, sending shudders all the way to university technology transfer offices.

Even one of the best-known super clusters must take steps to remain stable and sustainable as new competitors arise at home and abroad.

Cambridge, Mass., is acknowledged as one of the leading biotech clusters. The question now: how to maintain that edge in the face of global competition.